Advanced search
Publication Cover
Leukemia & Lymphoma Volume 31, 1998 - Issue 3-4
Submit an article Journal homepage
68
Views
25
CrossRef citations to date
0
Altmetric
Original Article

Anti- CD16/CD30 Bispecific Antibodies as Possible Treatment for Refractory Hodgkin's Disease

Frank Hartmann Medizinische Klinik I, Universitätskliniken des Saarlandes, D-66421, Homburg, Germany
,
Christoph Renner Medizinische Klinik I, Universitätskliniken des Saarlandes, D-66421, Homburg, Germany
,
Wolfram Jung Medizinische Klinik I, Universitätskliniken des Saarlandes, D-66421, Homburg, Germany
&
Michael Pfreundschuh Medizinische Klinik I, Universitätskliniken des Saarlandes, D-66421, Homburg, Germany
Pages 385-392 | Published online: 01 Jul 2009

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Yehuda E. Deutsch, Tamar Tadmor, Eckhard R. Podack & Joseph D. Rosenblatt. (2011) CD30: an important new target in hematologic malignancies. Leukemia & Lymphoma 52:9, pages 1641-1654.
Read now

Articles from other publishers (24)

Mary L. Faber, Robyn A. A. Oldham, Archana Thakur, Mary Jo Rademacher, Ewa Kubicka, Theresa A. Dlugi, Steven A. Gifford, William M. McKillop, Nathan J. Schloemer, Lawrence G. Lum & Jeffrey A. Medin. (2023) Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity. Frontiers in Immunology 14.
Crossref
Ziqing Chen, Ying Yang, Lisa L. Liu & Andreas Lundqvist. (2019) Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. Cancers 11:7, pages 1040.
Crossref
Jeffrey S. MillerLewis L. Lanier. (2019) Natural Killer Cells in Cancer Immunotherapy. Annual Review of Cancer Biology 3:1, pages 77-103.
Crossref
Yucai Wang, Grzegorz S. Nowakowski, Michael L. Wang & Stephen M. Ansell. (2018) Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. Journal of Hematology & Oncology 11:1.
Crossref
Geetika Bhatt, Kami Maddocks & Beth Christian. (2016) CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas. Current Hematologic Malignancy Reports 11:6, pages 480-491.
Crossref
Emilie M.J. van Brummelen, Willeke Ros, Gertjan Wolbink, Jos H. Beijnen & Jan H.M. Schellens. (2016) Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. The Oncologist 21:10, pages 1260-1268.
Crossref
Martin Felices, Todd R. Lenvik, Zachary B. Davis, Jeffrey S. Miller & Daniel A. Vallera. 2016. Natural Killer Cells. Natural Killer Cells 333 346 .
Bree Foley, Martin Felices, Frank Cichocki, Sarah Cooley, Michael R. Verneris & Jeffrey S. Miller. (2014) The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation ( HCT ) . Immunological Reviews 258:1, pages 45-63.
Crossref
Philippe Fournier & Volker Schirrmacher. (2012) Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer. BioDrugs 27:1, pages 35-53.
Crossref
Sergej M. Kiprijanov. 2011. Drug Delivery in Oncology. Drug Delivery in Oncology 441 482 .
Christian Kellner, Matthias Peipp & Thomas Valerius. 2011. Bispecific Antibodies. Bispecific Antibodies 217 241 .
Andres Forero-Torres, John P. Leonard, Anas Younes, Joseph D. Rosenblatt, Pauline Brice, Nancy L. Bartlett, Andre Bosly, Lauren Pinter-Brown, Dana Kennedy, Eric L. Sievers & Ajay K. Gopal. (2009) A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. British Journal of Haematology 146:2, pages 171-179.
Crossref
Pina M. Cardarelli, Maria-Cristina Moldovan-Loomis, Ben Preston, Amelia Black, David Passmore, Tseng-Hui Chen, Sharline Chen, Jie Liu, Michelle R. Kuhne, Mohan Srinivasan, Albert Assad, Alison Witte, Robert F. Graziano & David J. King. (2009) In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma . Clinical Cancer Research 15:10, pages 3376-3383.
Crossref
Walter M. Lewko & Robert K. Oldham. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy 155 276 .
Stephen M. Ansell, Steven M. Horwitz, Andreas Engert, Khuda Dad Khan, Thomas Lin, Roger Strair, Tibor Keler, Robert Graziano, Diann Blanset, Michael Yellin, Steven Fischkoff, Albert Assad & Peter Borchmann. (2007) Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma. Journal of Clinical Oncology 25:19, pages 2764-2769.
Crossref
Andrew Zelenetz. 2006. The Lymphomas. The Lymphomas 249 277 .
Arjan Diepstra, Ewerton M. Maggio, Anke van den Berg & Sibrand Poppema. 2004. Cancer Immunotherapy at the Crossroads. Cancer Immunotherapy at the Crossroads 315 334 .
Walter M. Lewko & Robert K. Oldham. 2003. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy 183 299 .
Bradley C. Ekstrand & Sandra J. Horning. (2002) Hodgkin's disease. Blood Reviews 16:2, pages 111-117.
Crossref
N Gruel, WH Fridman & JL Teillaud. (2001) Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-FcγR scFv on cancer cell surface. Gene Therapy 8:22, pages 1721-1728.
Crossref
M.L Harvey, T Illidge & P Johnson. (2001) Antibodies in the Treatment of Lymphoma. Clinical Oncology 13:4, pages 251-261.
Crossref
Henry B. Koon & Richard P. Junghans. (2000) Anti-CD30 antibody–based therapy. Current Opinion in Oncology 12:6, pages 588-593.
Crossref
Steven M. Horwitz & Sandra J. Horning. (2000) Advances in the treatment of Hodgkin’s lymphoma. Current Opinion in Hematology 7:4, pages 235-240.
Crossref
Maurizio Bendandi & Dan L. Longo. (1999) Biologic therapy for lymphoma. Current Opinion in Oncology 11:5, pages 343.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.